prof. Linos Vandekerckhove
- Work address
-
Psychosomatiek C. Heymanslaan 10
9000 Gent - Linos.Vandekerckhove@UGent.be
Show
Sort by
-
Relationship between HIV-1 env sequences from rebound plasma virus and viral outgrowth
(2019) -
Analytical treatment interruption (ATI) in patients with very small HIV reservoir
(2019) -
Increased numbers of intact HIV sequences in a4b7 T cells during acute seroconversion
(2019) -
- Journal Article
- open access
HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs
-
- Journal Article
- open access
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial
-
- Journal Article
- open access
Long non-coding RNAs and latent HIV – A search for novel targets for latency reversal
-
- Journal Article
- open access
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
-
Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years : final 96-week results of the NEAT022 study
-
Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1